Gene therapy for rare haematological and neurometabolic paediatric diseases
Authors:
- Vera GalloVGVera Gallo
- Alessandro AiutiAAAlessandro Aiuti
Open Access
- 13 June 2024
- journal article
- research article
- Published by Elsevier in Global Pediatrics
- Vol. 9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiencyNature Medicine, 2024
- Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editingAmerican Journal of Hematology, 2023
- Ensuring a future for gene therapy for rare diseasesNature Medicine, 2022
- A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disordersNature Communications, 2022
- Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessThe Lancet, 2022
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaNew England Journal of Medicine, 2021
- Gene therapy using haematopoietic stem and progenitor cellsNature Reviews Genetics, 2020
- Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical studyThe Lancet Haematology, 2019
- Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemiaNature Medicine, 2019
- Hematopoietic Stem-Cell Gene Therapy for Cerebral AdrenoleukodystrophyNew England Journal of Medicine, 2017